346 related articles for article (PubMed ID: 27288062)
1. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
Pabinger-Fasching I; Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
[No Abstract] [Full Text] [Related]
2. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
3. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
4. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
5. Use of high dose factor VIIa in hemophilia patients.
Hedner U
Adv Exp Med Biol; 2001; 489():75-88. PubMed ID: 11554593
[No Abstract] [Full Text] [Related]
6. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
7. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
8. [The current therapeutic bases for hemophilia].
Négrier C
Transfus Clin Biol; 2000 Jun; 7(3):257-8. PubMed ID: 10919215
[No Abstract] [Full Text] [Related]
9. [Treatment of hemophilia].
Stavem P; Hjort PF
Tidsskr Nor Laegeforen; 1970 Jul; 90(13):1413-8. PubMed ID: 5453192
[No Abstract] [Full Text] [Related]
10. [Hemophilia--present and past].
Terada H
Nihon Rinsho; 2008 Mar; 66(3):591-9. PubMed ID: 18330030
[TBL] [Abstract][Full Text] [Related]
11. Specific therapy in hemophilia.
Hutaff LW
N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
[No Abstract] [Full Text] [Related]
12. Advances in the care and treatment of children with hemophilia.
Manco-Johnson MJ
Adv Pediatr; 2010; 57(1):287-94. PubMed ID: 21056743
[No Abstract] [Full Text] [Related]
13. The current approach to hemophilia.
Morrison CJ
J Maine Med Assoc; 1974 Sep; 65(9):205-6. PubMed ID: 4416140
[No Abstract] [Full Text] [Related]
14. Current concepts in diagnosis and management of hemophilia.
Aledort LM
Hosp Pract (Off Ed); 1982 Oct; 17(10):77-84, 89-92. PubMed ID: 6811410
[No Abstract] [Full Text] [Related]
15. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources.
Aledort LM; Cohen M; Hilgartner M; Lipton R
Prog Clin Biol Res; 1984; 150():353-65. PubMed ID: 6431439
[No Abstract] [Full Text] [Related]
16. Molecular biology of coagulation.
Pavirani A; Bischoff R
Schweiz Med Wochenschr Suppl; 1991; 43():55-7. PubMed ID: 1843038
[No Abstract] [Full Text] [Related]
17. [New viewpoints in the treatment of hemophilia].
Göbel U
Dtsch Med Wochenschr; 1973 Sep; 98(39):1814-6. PubMed ID: 4583442
[No Abstract] [Full Text] [Related]
18. [Advances in the field of hemophilia therapy].
Loeliger EA; Veltkamp JJ
Ned Tijdschr Geneeskd; 1968 Sep; 112(36):1593-5. PubMed ID: 5680135
[No Abstract] [Full Text] [Related]
19. Prophylactic treatment in hemophilic patients with inhibitors.
Haya S
Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S14-S18. PubMed ID: 31517711
[TBL] [Abstract][Full Text] [Related]
20. Determinants of plasma factor VIIa levels in humans.
Eichinger S; Mannucci PM; Tradati F; Arbini AA; Rosenberg RD; Bauer KA
Blood; 1995 Oct; 86(8):3021-5. PubMed ID: 7579395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
